{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Endometrial+Cancer&page=3", "query": { "condition": "Stage III Endometrial Cancer", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 128, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Endometrial+Cancer&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Endometrial+Cancer&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T19:04:04.760Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01164735", "title": "Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer", "Stage IV Uterine Corpus Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 169, "start_date": "2010-01", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2024-08-14", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01164735" }, { "nct_id": "NCT00006377", "title": "Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": "2003-01", "has_results": false, "last_update_posted_date": "2013-06-18", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006377" }, { "nct_id": "NCT04269200", "title": "Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Neoplasms" ], "interventions": [ { "name": "olaparib", "type": "DRUG" }, { "name": "durvalumab", "type": "BIOLOGICAL" }, { "name": "durvalumab placebo", "type": "DRUG" }, { "name": "olaparib placebo", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "150 Years", "sex": "FEMALE", "summary": "18 Years to 150 Years · Female only" }, "enrollment_count": 805, "start_date": "2020-05-05", "completion_date": "2027-04-01", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 50, "location_summary": "Tucson, Arizona • Concord, California • La Jolla, California + 45 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04269200" }, { "nct_id": "NCT00082823", "title": "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "ziv-aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 2, "location_summary": "New York, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082823" }, { "nct_id": "NCT00245050", "title": "Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Drug/Agent Toxicity by Tissue/Organ", "Endometrial Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "pyridoxine hydrochloride", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DRUG" }, { "name": "doxorubicin HCL liposome", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 34, "start_date": "2004-04", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2011-12-30", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 8, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245050" }, { "nct_id": "NCT01005329", "title": "Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Stage IA Uterine Corpus Cancer AJCC v7", "Stage IB Uterine Corpus Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2009-11-06", "completion_date": "2013-09-22", "has_results": true, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 38, "location_summary": "Berkeley, California • Walnut Creek, California • Colorado Springs, Colorado + 31 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT01005329" }, { "nct_id": "NCT00002493", "title": "Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "low-LET photon therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": null, "start_date": "1992-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-14", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002493" }, { "nct_id": "NCT00285415", "title": "A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Endometrial Adenocarcinoma, Stage III A, B, C" ], "interventions": [ { "name": "Docetaxel and Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carilion Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 46, "start_date": "2005-04", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2021-02-05", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 2, "location_summary": "Greenville, South Carolina • Roanoke, Virginia", "locations": [ { "city": "Greenville", "state": "South Carolina" }, { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00285415" }, { "nct_id": "NCT02142803", "title": "TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Glioblastoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Solid Neoplasm", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-05-20", "completion_date": "2026-10-16", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Charlestown, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlestown", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02142803" }, { "nct_id": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Anaplastic Thyroid Cancer", "Bone Metastases", "Carcinoma of the Appendix", "Distal Urethral Cancer", "Fallopian Tube Cancer", "Gastrinoma", "Glucagonoma", "Inflammatory Breast Cancer", "Insulinoma", "Liver Metastases", "Localized Unresectable Adult Primary Liver Cancer", "Lung Metastases", "Male Breast Cancer", "Malignant Pericardial Effusion", "Malignant Pleural Effusion", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Parathyroid Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Newly Diagnosed Carcinoma of Unknown Primary", "Occult Non-small Cell Lung Cancer", "Pancreatic Polypeptide Tumor", "Primary Peritoneal Cavity Cancer", "Proximal Urethral Cancer", "Pulmonary Carcinoid Tumor", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adrenocortical Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Carcinoma of Unknown Primary", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Parathyroid Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Thyroid Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Skin Metastases", "Small Intestine Adenocarcinoma", "Somatostatinoma", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Adrenocortical Carcinoma", "Stage III Bladder Cancer", "Stage III Cervical Cancer", "Stage III Colon Cancer", "Stage III Endometrial Carcinoma", "Stage III Esophageal Cancer", "Stage III Follicular Thyroid Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Pancreatic Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Prostate Cancer", "Stage III Rectal Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Anal Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Anal Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Adrenocortical Carcinoma", "Stage IV Anal Cancer", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Gastric Cancer", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Papillary Thyroid Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Urethral Cancer Associated With Invasive Bladder Cancer", "WDHA Syndrome" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "ABI-007/carboplatin/trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-10-05T19:04:04.760Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004074" } ] }